Journal article
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan
- Abstract:
-
Background
First-line schizontocidal treatment for uncomplicated malaria in the Republic of the Sudan is artesunate (total dose 12 mg/kg) plus Sulphadoxine/pyrimethamine (25/1.25 mg/kg) (AS/SP). Patients with Plasmodium vivax are also treated with 14 days primaquine (total dose 3.5 mg/kg) (PQ). The aim of this study was to assess the efficacy of the national policy.
Methods
Patients above 1 year, with microscopy-confirmed, Plasmodium falciparum and/or P. vivax mal...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bill and Melinda Gates Foundation
More from this funder
the Australian Department of Foreign Affairs and Trade
More from this funder
Bibliographic Details
- Publisher:
- BioMed Central Publisher's website
- Journal:
- Malaria Journal Journal website
- Volume:
- 17
- Issue:
- 1
- Pages:
- 117
- Publication date:
- 2018-03-01
- Acceptance date:
- 2018-03-08
- DOI:
- EISSN:
-
1475-2875
- Pmid:
-
29548285
- Source identifiers:
-
831391
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:831391
- UUID:
-
uuid:c7918e8f-3819-4370-b480-e2bf71e9f234
- Local pid:
- pubs:831391
- Deposit date:
- 2018-03-26
Terms of use
- Copyright holder:
- Price et al
- Copyright date:
- 2018
- Notes:
- © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record